Aspen secures licensing agreement to enter GLP-1 market
Aspen Pharmacare has secured a licensing agreement to enter the GLP-1 agonist market, positioning it for growth in diabetes and obesity treatment solutions.
This article is for Health Matters subscribers
Subscribers read every article in full, receive the daily briefing and have access to the complete archive.